To determine the clinical significance of CCR8+ Tregs in lung cancer, we evaluated the frequency of CCR8+ Tregs in tumor-infiltrating CD45+ cells in 50 lung cancer patients by flow cytometry and analyzed the correlation with clinical stage and outcome. This evidence concerns the gene PTPRC and lung cancer.